Constella™(EU)–Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs

References

• 1  Albericio F, Kruger HG. Therapeutic peptides. Future Med. Chem.4(12),1527–1531 (2012).
  CASGoogle Scholar
• 2  Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov. Today15,40–56 (2010).
  Medline CASGoogle Scholar
• 3  Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology130(5),1377–1390 (2006).
  MedlineGoogle Scholar
• 4  Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology130(5),1480–1491 (2006).
  MedlineGoogle Scholar
• 5  Wong RK, Palsson O, Turner MJ et al. Inability of the Rome III criteria to distinguish functional constipation form constipation-subtype irritable bowel syndrome. Am. J. Gastroenterol.105,2228–2234 (2010).
  MedlineGoogle Scholar
• 6  Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol. Motil.20(Suppl. 1),121–129 (2008).
  MedlineGoogle Scholar
• 7  Sun SX, Dibonaventura M, Purayidathil FW, Wagner JS, Dabbous O, Mody R. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig. Dis. Sci.56,2688–2695 (2011).
  MedlineGoogle Scholar
• 8  Faresjo A, Grodzinsky E, Johansson S, Wallander MA, Timpka T, Akerlind I. Population-based case-control study of work and psychosocial problems in patients with irritable bowel syndrome-women are more seriously affected than men. Am. J. Gastroenterol.102,371–379 (2007).
  MedlineGoogle Scholar
• 9  Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clinical Gastroenterol. Hepatol.10(7),712–721 (2012).
  MedlineGoogle Scholar
• 10  Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am. J. Gastroenterol.106,1582–1591 (2011).
  MedlineGoogle Scholar
• 11  Ford AC, Talley NJ. Irritable bowel syndrome. BMJ345,e5836 (2012).
  MedlineGoogle Scholar
• 12  Hungin AP, Whorwell PJ, Tack J et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. Aliment. Pharmacol. Ther.17(5),643–650 (2003).
  Medline CASGoogle Scholar
• 13  Ricci JF. Irritable bowel syndrome: a comparison of the economic (direct and indirect) burden in four European countries. Gut51,A107 (2002).
  Google Scholar
• 14  Quigley EM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig. Liver Dis.38(10),717–723 (2006).
  Medline CASGoogle Scholar
• 15  Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J. Manag. Care Pharm.10(4),299–309 (2004).
  MedlineGoogle Scholar
• 16  Camilleri M. Etiology and pathophysiology of irritable bowel syndrome and chronic constipation. Adv. Studies Med.5(10b),S955–S964 (2005).
  Google Scholar
• 17  Öhman L, Simrén M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Digest. Liver Dis.39,201–215 (2007).
  CASGoogle Scholar
• 18  Wood JD. Neuropathopysiology of functional gastrointestinal disorders. World J. Gastroenterol.13(9),1313–1332 (2007).
  Medline CASGoogle Scholar
• 19  Andresen V, Camilleri M. Irritable bowel syndrome recent and novel therapeutic approaches. Drugs66(8),1073–1088 (2006).
  Medline CASGoogle Scholar
• 20  Menees S, Saad R, Chey WD. Agents that act luminally to treat diarrhea and constipation. Nat. Rev. Gastroenterol. Hepatol.9,661–674 (2012).
  Medline CASGoogle Scholar
• 21  Camilleri M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clinical Pharmacol. Ther.91(1),44–59 (2012).
  Medline CASGoogle Scholar
• 22  Evans BW, Clark WK, Moore DJ, Whorwell PJ. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation. Cochrane Database Syst. Rev.17(4),CD003960 (2007).
  Google Scholar
• 23  Tack J, Camilleri M, Chang L et al. Systematic review: cardiovascular safety profile of 5-HT₄ agonists developed for gastrointestinal disorders. Aliment. Pharmacol. Ther.35,745–767 (2012).
  Medline CASGoogle Scholar
• 24  Quigley EMM. Prucalopride: safety, efficacy and potential applications. Therap. Adv. Gastroenterol.5(1),23–30 (2012).
  Medline CASGoogle Scholar
• 25  Tack J, Corsetti M. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert Opin. Drug Metab. Toxicol.8(10),1327–1335 (2012).
  Medline CASGoogle Scholar
• 26  Goldberg M, Li YP, Johanson JF et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT₄ agonist with high intrinsic activity, in chronic idiopathic constipation – a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment. Pharmacol. Ther.32(9),1102–1112 (2010).
  Medline CASGoogle Scholar
• 27  Long DD, Armstrong SR, Beattie DT et al. Discovery, oral pharmacokinetics and in vivo efficacy of velusetrag, a highly selective 5-HT(4) receptor agonist that has achieved proof-of-concept in patients with chronic idiopathic constipation. Bioorg. Med. Chem. Lett.22(19),6048–6052 (2012).
  Medline CASGoogle Scholar
• 28  Beattie DT, Armstrong SR, Vickery RG. The pharmacology of TD-8954, a potent and selective 5-HT₄ receptor agonist with gastrointestinal prokinetic properties. Front. Pharmacol.2,25 (2011).
  MedlineGoogle Scholar
• 29  Schey R, Rao SS. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig. Dis. Sci.56(6),1619–1625 (2011).
  Medline CASGoogle Scholar
• 30  Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin. Drug Saf.11(5),841–850 (2012).
  Medline CASGoogle Scholar
• 31  Cremonini F, Camilleri M, McKinzie S et al. Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am. J. Gastroenterol.100(3),652–663 (2005).
  Medline CASGoogle Scholar
• 32  McWilliams V, Whiteside G, McKeage K. Linaclotide: first global approval. Drugs72(16),2167–2175 (2012).
  Medline CASGoogle Scholar
• 33  Quigley EM, Tack J, Chey WD et al. Randomized clinical trials: linaclotide Phase 3 studies in IBS-C – a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment. Pharmacol. Ther.37(1),49–61 (2013).
  Medline CASGoogle Scholar
• 34  Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin. Investig. Drugs.22(2),277–284 (2013).
  Medline CASGoogle Scholar
• 35  Basu N, Arshad N, Visweswariah SS. Receptor guanylyl cyclase C (GC-C): regulation and signal transduction. Mol. Cell. Biochem.334,67–80 (2010).
  Medline CASGoogle Scholar
• 36  Lucas KA, Pitari GM, Kazerounian S et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol. Rev.52,375–413 (2000).
  Medline CASGoogle Scholar
• 37  Currie MG, Fok KF, Kato J et al. Guanylin: an endogenous activator of intestinal guanylate cyclase. Proc. Natl Acad. Sci. USA89,947–951 (1992).
  Medline CASGoogle Scholar
• 38  Hamna FK, Forte LR, Eber SL et al. Uroguanylin: structure and activity of a second endogenous peptides that stimulates intestinal guanylate cyclase. Proc. Natl Acad. Sci. USA90,10464–10468 (1993).
  MedlineGoogle Scholar
• 39  Arshad N, Visweswariah SS. The multiple and enigmatic roles of guanylyl cyclase C in intestinal homeostasis. FEBS Lett.586(18),2835–2840 (2012).
  Medline CASGoogle Scholar
• 40  Forte LR. Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics. Pharmacol. Ther.104,137–162 (2004).
  Medline CASGoogle Scholar
• 41  Lacy BE, Levenick JM, Crowell M. Chronic constipation: new diagnostic and treatment approaches. Ther. Adv. Gastroenterol.5(4),233–247 (2012).
  MedlineGoogle Scholar
• 42  Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr. Opin. Mol. Ther.9,403–410 (2007).
  Medline CASGoogle Scholar
• 43  Solinga R, Kessler, M, Busby, R. and Currie, M. A comparison of the physical and pharmacological properties of plecanatide (SP-304) and the human hormone uroguanylin. ACJ11(S2),332 (2011).
  Google Scholar
• 44  Lin JE, Valentino M, Marszalowicz G et al. Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics. Toxins2,2028–2054 (2010).
  Medline CASGoogle Scholar
• 45  Staples SJ, Asher SE, Giannella RA. Purification and characterization of heat-stable enterotoxin produced by a strain of E. coli pathogenic for man. J. Biol. Chem.255,4716–4721 (1980).
  Medline CASGoogle Scholar
• 46  Yoshimura S, Ikemura H, Watanabe H et al. Essential structure for full enterotoxigenic activity of heat-stable enterotoxin produced by enterotoxigenic Escherichia coli. FEBS Lett.181,138–142 (1985).
  Medline CASGoogle Scholar
• 47  Waldmann SA, O’Hanley P. Influence of a glycine or proline substitution on the functional properties of a 14-amino-acid analog of Escherichia coli heat-satble enterotoxin. Infect. Immun.57,2420–2424 (1989).
  MedlineGoogle Scholar
• 48  Matecko I, Burmann BM, Schweimer K et al. Structural characterization of the E. coli heat stable enterotoxin STh. Open Spectrosc. J.2,34–39 (2008).
  CASGoogle Scholar
• 49  Carpick BW, Gariepy J. Structural characterization of functionally important regions of the Escherichia coli heat-stable enterotoxin ST1b. Biochemistry30,4803–4809 (1991).
  Medline CASGoogle Scholar
• 50  Skelton NJ, Garcia KC, Goeddel DV, Quan C, Burnier JP. Determination of the solution structure of the peptide hormone guanylin: observation of a novel form of topological stereoisomerism. Biochemistry33,13581–13592 (1994).
  Medline CASGoogle Scholar
• 51  Marx UC, Klodt J, Meyer M et al. One peptide, two topologies: structure and interconversion dynamics of human uroguanylin isomers. J. Pept. Res.52,229–240 (1998).
  Medline CASGoogle Scholar
• 52  Weiglmeier PR, Rösch P, Berkner H. Cure and curse: E. coli heat-stable enterotoxin and its receptor guanylyl cyclase C. Toxins2,2213–2229 (2010).
  Medline CASGoogle Scholar
• 53  Gariépy J, Judd AK, Schoolnik GK. Importance of disulfide bridges in the structure and activity of Escherichia coli enterotoxin ST1b. Proc. Natl Acad. Sci. USA84,8907–8911 (1987).
  Medline CASGoogle Scholar
• 54  Carpick BW, Gariepy J. The Escherichia coli heat-stable enterotoxin is a long-lived superagonist of guanylin. Infect. Immun.61,4710–4715 (1993).
  Medline CASGoogle Scholar
• 55  Hamra FK, Eber SL, Chin DT, Currie MG, Forte LR. Regulation of intestinal uroguanylin/guanylin receptor-mediated responses by mucosal acidity. Proc. Natl Acad. Sci. USA94,2705–2710 (1997).
  Medline CASGoogle Scholar
• 56  Bryant AP, Busby RW, Bartolini WP et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci.86,760–765 (2010).
  Medline CASGoogle Scholar
• 57  Busby RW, Bryant AP, Bartolini WP et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur. J. Pharmacol.649,328–335 (2010).
  Medline CASGoogle Scholar
• 58  Kessler MM, Busby RW, Wakefield JD et al. Rat intestinal metabolism of linaclotide, a therapeutic agent in clinical development for the treatment of IBS-C and chronic constipation. Drug Metab. Rev.40(Suppl. 3),213–214 (2008).
  Google Scholar
• 59  Bryant AP, Busby RW, Cordero EA. MD-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Gastroenterology128,464 (2005).
  Google Scholar
• 60  Eutamene H, Bradesi S, Larauche M et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol. Motil.22,312–e84 (2010).
  Medline CASGoogle Scholar
• 61  Johnston JM, Kurtz CB, MacDougall JE et al. Linaclotide improves abdominal pain and bowel habits in a Phase 2b study of patients with irritable bowel syndrome with constipation. Gastroenterology139,1877–1886 (2010).
  Medline CASGoogle Scholar
• 62  Ustinova E, Reza T, Currie M, Pezzone M. Oral cyclic guanosine monophosphate (cGMP) desensitizes colonic afferents in an animal model of experimental colitis. Am. J. Gastroenterol.103(Suppl. 1),S187 (2008).
  Google Scholar
• 63  Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: a review from the patient’s perspective. Ther. Clin. Risk. Manag.4(1),269–286 (2008).
  MedlineGoogle Scholar
• 64  Soltero R. Oral protein and peptide drug delivery. In: Drug Delivery Principles and Applications. Wang B, Siahaan T, Soltero, R (Eds). Wiley and Sons, Inc. Publications, NJ, USA, 189–200 (2005).
  Google Scholar
• 65  Antosova Z, Mackova M, Kral V, Macek T. Therapeutic application of peptides and proteins: parenteral forever? Trends Biotechnol.27(11),628–635 (2009).
  Medline CASGoogle Scholar
• 66  Cheek S, Krishna SS, Grishin NV. Structural classification of small, disulfide-rich protein domains. J. Mol. Biol.359,215–237 (2006).
  Medline CASGoogle Scholar
• 67  Ireland DC, Clark RJ, Daly NL, Craik DJ. Isolation, sequencing, and structure-activity relationships of cyclotides. J. Nat. Prod.73,1610–1622 (2010).
  Medline CASGoogle Scholar
• 68  King GF. Venoms as a platform for human drugs: translating toxins into therapeutics. Expert Opin. Biol. Ther.11,1469–1484 (2011).
  Medline CASGoogle Scholar
• 69  King GF, Hardy MC. Spider-venom peptides: structure, pharmacology, and potential for control of insect pests. Annu. Rev. Entomol.58,475–496 (2013).
  Medline CASGoogle Scholar
• 70  Teichert RW, Jimenez EC, Olivera BM. Biology and Pharmacology of Conotoxins. In: Botulinum Toxin: Therapeutic Clinical Practice and Science. Elsevier Inc., PA, USA (2009).
  Google Scholar
• 71  Halai R, Craik DJ. Conotoxins: natural product drug leads. Nat. Prod. Rep.26,526–536 (2009).
  Medline CASGoogle Scholar
• 72  Dubreuil JD. The Comprehensive Sourcebook of Bacterial Protein Toxins. Elsevier Ltd, London, UK, 798–817 (2006).
  Google Scholar
• 73  Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol.3,710–720 (2003).
  Medline CASGoogle Scholar
• 74  Moore SJ, Leung CL, Cochran JR. Knottins: disulfide-bonded therapeutic and diagnostic peptides. Drug Discov. Today: Tech.9,e3–e11 (2012).
  CASGoogle Scholar
• 75  Craik DJ, Clark RJ. Daly NL. Cyclotides and conotoxins ultra-stable disulfide-rich peptides. Chim. Oggi.26(4),20–22 (2008).
  CASGoogle Scholar
• 76  Cain C. Excited about cycling. BioCentury20(38),7–25 (2012).
  Google Scholar
• 77  Fiskerstrand T, Arshad N, Haukanes BI et al. Familial diarrhea syndrome caused by an activating GUCY2C mutation. N. Engl. J. Med.366,1586–1595 (2012).
  Medline CASGoogle Scholar
• 101  US FDA announcement. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm
  Google Scholar
• 102  European Medicines Agency announcement. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002490/smops/Positive/human_smop_000414.jsp&mid=WC0b01ac058001d127
  Google Scholar
• 103  Decision Resources Group. www.decisionresources.com/News-and-Events/Press-Releases/irritable-bowel-syndrome-050912
  Google Scholar
• 104  Hanmi Pharmaceuticals Co. Ltd, Global Licensing–Out. www.hanmipharm.com/eng/business/global_out01.asp
  Google Scholar
• 105  Dainippon Sumitomo Pharma. Profile of major products under development (as of October 31 2012). www.ds-pharma.com/rd/clinical/pipeline_profile.html
  Google Scholar
• 106  Synergy Pharmaceuticals: compounds in development. www.synergypharma.com/pipeline/overview
  Google Scholar
• 107  The plecanatide Chronic Idiopathic Constipation (CIC) study. www.clinicaltrials.gov/show/NCT01429987
  Google Scholar
• 108  The plecanatide irritable bowel syndrome with constipation study (IBS-C) (CIBS). www.clinicaltrials.gov/show/NCT01722318
  Google Scholar
• 109  Ardelyx RDX5791. http://ardelyx.com/rdx5791
  Google Scholar
• 110  A study to evaluate the safety and efficacy of RDX5791 for the treatment of constipation predominant irritable bowel syndrome (IBS-C). http://clinicaltrials.gov/show/NCT01340053
  Google Scholar
• 111  Thomson Reuters Integrity. Prous Science. http://integrity.thomson-pharma.com
  Google Scholar